XTL Biopharma files to raise $40m on Nasdaq
Dr. Aharon Schwartz argues that patents impede rather than assist new drug development.
"Everyone knows that the pharmaceutical industry cannot exist without innovation and innovation cannot exist without Intellectual Property (IP)," said Dr. Aharon Schwartz in his opening remarks in a lecture at a seminar on the subject recently held by law firms S. Horowitz and IP law specialists Kenyon & Kenyon LLP.
Schwartz added, "I could bring a molecule to the major pharmaceutical firms tomorrow that gets rid of cancer in 24 hours. But if I don't have a patent on it they would say thank you very much and goodbye."
Schwartz recently stepped down as Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) VP Innovative Ventures but continues to serve as chairman of several companies including BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) and Biocancell Therapeutics Ltd. (TASE:BICL).
If the lawyers in the audience thought that Schwartz was going to justify the importance of their work, then they were in for a surprise. Schwartz asked what would happen if the pharmaceutical industry completely discarded the concept of IP, and led the audience to draw the conclusion that this was the way to save the pharmaceutical industry.
Schwartz does not really believe that it would be possible to implement such a radical approach tomorrow or any time soon, but he told "Globes", "It is clear to me that the route we have taken so far has led to a dead end.
He explained, "The pharmaceutical industry's business model, which is protected by IP, was until recently very successful. It is based on the fact that companies successfully bring to market just a few products and are defined as a monopoly in these products through patents, and thus are able to recoup their overall investment in R&D."
The success of this model can be seen from the bottom line - pharmaceutical companies have in recent decades reported significantly high profits compared with average Fortune 500 companies.
Despite this Schwartz believes that this model is changing. "In the pharmaceutical industry we are almost not curing patients. We are only treating them. And I can tell you from my own personal experience that I am aging every day and that's true for all of us. And as you get older you don't get healthier."
An aging population is causing health costs to rise. These budgetary restrictions have hit the financial results of pharmaceutical companies. "Their current growth of 2-4% compared with 10-15% several decades ago is insufficient," he said.
What else has gone wrong? Pharmaceutical companies are investing more than in the past in innovation but output is declining and the number of new products is almost zero compared with the 1990s. "They've tried to do everything. Spinoffs, acquisitions, insourcing, outsourcing, splitting large companies into small divisions in order to better operate as if they are start ups and nothing has helped."
Schwartz claims that the main hope for innovation in the market currently comes from two directions. Firstly, customized treatments in which every treatment is only for the patient for whom it would be most effective, at the right time and in the correct dosage. Secondly, focused treatment that better directs the molecule to the organ it is designed to treat. "
He said, "If someone can cause these two options to work, it would be wonderful." He gives credit to customized treatments such as Herceptin and Glivec that have transformed the lives of patients. "Glivec attacks the mutations that are found in 90% of cancer patients treated by the drug. 90% of patients is customization?"
This discussion leads Schwartz to deal with the billion dollar question: "Why is nothing working today? Why did everything work at the end of the 20th century?" The answer in his opinion is that the biological mechanisms that helped develop drugs in the past were simpler. "They have now invested in biological and molecular mechanisms that are terribly complicated. It is very difficult to operate in this environment where they don't really know what is happening."
Nevertheless, medicines continue to be protected by patents. "Global prescription drug sales this year will total $600 billion of which $540 billion are the costs of the monopolies. If the monopoly yields innovation then that's excellent, but the monopolies don't result in innovation so why reward them?"
If IP was discarded, said Schwartz, it would be possible to invest, for example, $250 billion of global GDP in research to promote biological molecular science and the balance, about $320 billion could simply be repaid to consumers or collected as a tax to make existing treatments accessible for patients that simply don't have the money for these drugs. Such an allocation would improve global health more than new drugs that would extend the lives of a few patients by several years."
Published by Globes [online], Israel business news - www.globes-online.com - on December 31, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.